相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
A novel radiolytic rotenone derivative, rotenoisin A, displays potent anticarcinogenic activity in breast cancer cells
Dong-ho Bak et al.
JOURNAL OF RADIATION RESEARCH (2021)
Design, synthesis, biological evaluation, and docking studies of novel (imidazol-5-yl)pyrimidine-based derivatives as dual BRAFV600E/p38α inhibitors
Eslam M. H. Ali et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)
Discovery of New Imidazo[2,1-b]thiazole Derivatives as Potent Pan-RAF Inhibitors with Promising In Vitro and In Vivo Anti-melanoma Activity
Mohammed S. Abdel-Maksoud et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Design and synthesis of novel parabanic acid derivatives as anticonvulsants
Mona Elsayed Aboutabl et al.
BIOORGANIC CHEMISTRY (2020)
Structural and biological survey of 7-chloro-4-(piperazin-1-yl)quinoline and its derivatives
Aida M. Abd El-Sattar El-Azzouny et al.
DRUG DEVELOPMENT RESEARCH (2020)
Design and synthesis of novel pyrrolo[2,3-b]pyridine derivatives targeting V600EBRAF
Mohammed S. Abdel-Maksoud et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2020)
Green synthesis and biological screening of some fluorinated pyrazole chalcones in search of potent anti-inflammatory and analgesic agents
Shravan Y. Jadhav et al.
EGYPTIAN PHARMACEUTICAL JOURNAL (2020)
Bioactive glycoalkaloides isolated from Solanum melongena fruit peels with potential anticancer properties against hepatocellular carcinoma cells
Mostafa I. Fekry et al.
SCIENTIFIC REPORTS (2019)
Anticancer profile of newly synthesized BRAF inhibitors possess 5-(pyrimidin-4-yl)imidazo[2,1-b]thiazole scaffold
Mohammed S. Abdel-Maksouda et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2019)
Anti-Inflammatory Mechanisms of Koreanaside A, a Lignan Isolated from the Flower of Forsythia koreana, against LPS-Induced Macrophage Activation and DSS-Induced Colitis Mice: The Crucial Role of AP-1, NF-κB, and JAK/STAT Signaling
Tae-Woo Kim et al.
CELLS (2019)
Design, synthesis and anticancer evaluation of novel 1,3-benzodioxoles and 1,4-benzodioxines
Rasha Mohamed Hassan et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2019)
Design, synthesis, and anticancer activity of imidazo[2,1-b]oxazole-based RAF kinase inhibitors
Mohammed S. Abdel-Maksoud et al.
BIOORGANIC CHEMISTRY (2019)
Design, synthesis, in vitro anticancer evaluation, kinase inhibitory effects, and pharmacokinetic profile of new 1,3,4-triarylpyrazole derivatives possessing terminal sulfonamide moiety
Mohammed S. Abdel-Maksoud et al.
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY (2019)
Recent advances in the discovery of small molecule c-Met Kinase inhibitors
Palak K. Parikh et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
Reinhard Dummer et al.
LANCET ONCOLOGY (2018)
Design, synthesis and biological screening of 2-aminobenzamides as selective HDAC3 inhibitors with promising anticancer effects
Prakruti Trivedi et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2018)
Synthesis of New Triarylpyrazole Derivatives Possessing Terminal Sulfonamide Moiety and Their Inhibitory Effects on PGE(2) and Nitric Oxide Productions in Lipopolysaccharide-Induced RAW 264.7 Macrophages
Mohammed S. Abdel-Maksoud et al.
MOLECULES (2018)
Synthesis, in vitro Antiproliferative and Antiinflammatory Activities, and Kinase Inhibitory effects of New 1,3,4-triarylpyrazole Derivatives
Mohammed I. El-Gamal et al.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY (2017)
Design and synthesis of new RAF kinase-inhibiting antiproliferative quinoline derivatives. Part 2: Diarylurea derivatives
Mohammed I. El-Gamal et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2017)
Design and synthesis of sulfonamide-substituted diphenylpyrimidines (SFA-DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors with improved activity toward B-cell lymphoblastic leukemia
He Liu et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2017)
Design, synthesis and biological evaluation of sulfonamide-substituted diphenylpyrimidine derivatives (Sul-DPPYs) as potent focal adhesion kinase (FAK) inhibitors with antitumor activity
Menghua Qu et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2017)
Novel fluorinated docetaxel analog for anti-hepatoma: Molecular docking and biological evaluation
Yun-peng Hao et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2016)
Broad-spectrum antiproliferative activity of a series of 6-(4-fluorophenyl)-5-(2-substituted pyrimidin-4-yl)imidazo[2,1-b]thiazole derivatives
Mohammed S. Abdel-Maksoud et al.
MEDICINAL CHEMISTRY RESEARCH (2016)
Non-small cell lung cancer: current treatment and future advances
Cecilia Zappa et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2016)
Design and synthesis of certain substituted cycloalkanecarboxamides structurally related to safinamide with anticonvulsant potential
Mohamed N. Aboul-Enein et al.
RESEARCH ON CHEMICAL INTERMEDIATES (2015)
Synthesis and antitumor activity of pyrido [2,3-d]pyrimidine and pyrido[2,3-d] [1,2,4]triazolo[4,3-a]pyrimidine derivatives that induce apoptosis through G1 cell-cycle arrest
Mohamed Fares et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2014)
Clinical development of dabrafenib in BRAF mutant melanoma and other malignancies
Geoffrey T. Gibney et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2013)
Ruxolitinib: The First FDA Approved Therapy for the Treatment of Myelofibrosis
John Mascarenhas et al.
CLINICAL CANCER RESEARCH (2012)
Synthesis, Molecular Properties Prediction, and Anti-staphylococcal Activity of N-Acylhydrazones and New 1,3,4-Oxadiazole Derivatives
Cledualdo Soares de Oliveira et al.
MOLECULES (2012)
Vemurafenib: the first drug approved for BRAF-mutant cancer
Gideon Bollag et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
Prostaglandins and Inflammation
Emanuela Ricciotti et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2011)
Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal-Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)
J. Jean Cui et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
Cell Signaling by Receptor Tyrosine Kinases
Mark A. Lemmon et al.
CELL (2010)
Sorafenib A Review of its Use in Advanced Hepatocellular Carcinoma
Gillian M. Keating et al.
DRUGS (2009)
Synthesis and biological evaluation of some thiazolyl and thiadiazolyl derivatives of 1H-pyrazole as anti-inflammatory antimicrobial agents
Adnan A. Bekhit et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2008)
Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling
Scott M. Wilhelm et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
P. J. Roberts et al.
ONCOGENE (2007)
Tyrosine kinases as targets for cancer therapy
DS Krause et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Chemokine production and E-selectin expression in activated endothelial cells are inhibited by p38 MAPK (mitogen activated protein kinase) inhibitor RWJ 67657
J Westra et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2005)
Phosphodiesterase inhibitors stimulate osteoclast formation via TRANCE/RANKL expression in osteoblasts: possible involvement of ERK and p38 MAPK pathways
M Takami et al.
FEBS LETTERS (2005)
The biology of p38 kinase: A central role in inflammation
GL Schieven
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2005)
Timeline - The discovery of receptor tyrosine kinases: targets for cancer therapy
A Gschwind et al.
NATURE REVIEWS CANCER (2004)
Signal transduction by tumor necrosis factor and gene regulation of the inflammatory cytokine interleukin-6
W Vanden Berghe et al.
BIOCHEMICAL PHARMACOLOGY (2000)
分享论文
